Lixisenatide provided a significant reduction in HbA1c at Week 24 versus placebo ( LS mean : -0.85 % vs. -0.10 % ; p < 0.0001 ) and more patients achieved HbA1c < 7.0 % ( 36.4 % vs. 13.5 % ; p < 0.0001 ) .